Tempest Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Tempest Therapeutics (TPST) received a notice from Nasdaq on November 4, 2026, for its stock closing below $1.00 for 30 days, violating Listing Rule 5550(a)(2). The company has until May 3, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 days. The notice does not immediately affect its Nasdaq listing.
How this was made
The 30-second read
Why it matters
The notice signals a compliance risk that typically depresses share price until the company meets the bid‑price threshold.
Market read
The compliance notice is a material corporate action for TPST, creating short‑term downside risk and potential trading opportunities.
What to watch
Potential for a reverse split or a capital raise to boost the share price, which could mitigate delisting risk.
Background
Tempest Therapeutics (TPST) received a Nasdaq Listing Rule 5550(a)(2) notice on Nov 4, 2026 for failing the $1.00 minimum bid price requirement.
Ticker impact
Nasdaq notified Tempest Therapeutics that its share price fell below the $1.00 minimum bid for 30 days, triggering a compliance notice.
downward pressure as investors price in the risk of a potential delisting or forced reverse split
A bid-price deficiency is a material corporate action for a micro‑cap biotech; market typically reacts negatively to such notices.
Market effects
Other small‑cap biotech stocks may see heightened scrutiny of bid‑price compliance.
US Nasdaq micro‑cap segment could experience modest sell pressure.
Limited to investors tracking US listed micro‑caps.
Counterpoint
If the company quickly regains compliance, the stock could rebound sharply on short‑covering.
Key entities
- companyTempest Therapeutics, Inc.
Biotech firm listed on Nasdaq under ticker TPST.
- exchangeNasdaq
Issuer of the compliance notice under Listing Rule 5550(a)(2).